COVID-19 vaccine AZD1222 showed robust immune responses in ...
Rapid induction of antibodies and T-cells against the SARS-CoV-2 virus may be important in protection against COVID-19. COV001. COV001 is a Phase I/II single-blinded randomised controlled trial to determine safety, immunogenicity and efficacy of the COVID-19 vaccine candidate AZD1222 in up to 1,077 healthy adults in five trial centres in the UK.
DA: 63 PA: 58 MOZ Rank: 75